A-dmDT390-bisFv(UCHT1)

DB16307InvestigationalProtein Based Therapies

A-dmDT390-bisFv(UCHT1) is under investigation in clinical trial NCT02943642 (Safety and Effectiveness of A-dmdt390-bisfv(ucht1) Fusion Protein in Subjects With Mycosis Fungoides).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain and Elongation factor 2
Curator reviewed
Also known as: Anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) · Recombinant anti-cdr-bi-single-chain-fv-diphtheria toxin fusion protein · Recombinant anti-cdr-bi-single-chain-fv-diptheria toxin fusion protein · Resimmune
Code names: A-dmDT390-bisFv(UCHT1) · LAX-699

Resolves to

Compound

UNIIP7MQ9ZOQ82CAS1470038-56-2

Targets

P07766CD3EP13639EEF2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with A-dmDT390-bisFv(UCHT1), and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account